Elevation Oncology Inc. Announces Regulatory Changes Following Merger and Delisting from Nasdaq
I'm PortAI, I can summarize articles.
Elevation Oncology Inc. has announced regulatory changes following its merger with Concentra Biosciences, LLC, completed on July 23, 2025. The company's shares have been delisted from the Nasdaq Stock Market, and Elevation has requested a suspension of trading and filed a Notification of Removal from Listing with the SEC. The surviving corporation will terminate the registration of its shares and suspend reporting obligations under the Securities Exchange Act. All previous directors have resigned, with new leadership from Merger Sub taking over.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments